GRADE: Incorporating considerations of resources use into grading recommendations

BMJ

Volumn 336, Issue 7654, 2008, Pages 1170-1173

  Guyatt, Gordon H ^a   Oxman, Andrew D ^b   Kunz, Regina ^c   Jaeschke, Roman ^a   Helfand, Mark ^d   Liberati, Alessandro ^e   Vist, Gunn E ^b   Schünemann, Holger J ^f  

^a MCMASTER UNIVERSITY   (Canada)

^b NORWEGIAN KNOWLEDGE CENTRE FOR THE HEALTH SERVICES   (Norway)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d PORTLAND VA MEDICAL CENTER   (United States)

^e UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^f REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL PRACTICE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; EVALUATION; EVIDENCE BASED PRACTICE; GRADING OF RECOMMENDATIONS ASSESSMENT DEVELOPMENT AND EVALUATION; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HUMAN; MEDICAL DECISION MAKING; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; RESOURCE ALLOCATION; RESPONSIBILITY; TREATMENT OUTCOME; COST; DECISION MAKING; ECONOMICS; EVIDENCE BASED MEDICINE; REVIEW; STATISTICAL MODEL; UTILIZATION REVIEW;

COSTS AND COST ANALYSIS; DECISION MAKING; EVIDENCE-BASED MEDICINE; HEALTH PLANNING GUIDELINES; HEALTH RESOURCES; MODELS, ECONOMIC; QUALITY ASSURANCE, HEALTH CARE;

EID: 44449179830     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Guyatt G, Baumann M, Pauker S, Halperin J, Maurer J, Owens DK, et al. Addressing resource allocation issues in recommendations from clinical practice guideline panels: suggestions from an American College of Chest Physicians task force. Chest 2006;129:182-7.
2. Eddy DM. Comparing benefits and harms: the balance sheet. JAMA 1990;263:2493, 2498, 2501.
3. Magpie Trial Collaborative Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The magpie trial: a randomised placebo-controlled trial. Lancet 2002;359:1877-90.
4. Simon J, Gray A, Duley L. Cost-effectiveness of prophylactic magnesium sulphate for 9996 women with pre-eclampsia from 33 countries: economic evaluation of the magpie trial. Br J Obstet Gynaecol 2006;113:144-51.
5. Montori VM, Jaeschke R, Schünemann HJ, Bhandari M, Brozek JL, Devereaux PJ, et al. Users' guide to detecting misleading claims in clinical research reports. BMJ 2004;329:1093-6.
6. Luce B, Manning W, Siegel J. Estimating costs in cost-effectiveness analysis. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-effectiveness in health and medicine. Oxford: Oxford University Press, 1996: 176-213.
7. Friedberg M, Saffran B, Stinson TJ, Nelson W, Bennett CL. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA 1999;282:1453-7.
8. Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ 1997;16:1-31.
9. Owens DK. Interpretation of cost-effectiveness analyses. J Gen Intern Med 1998;13:716-7.
10. Gold M, Siegel JE, Russell LB, Weinstein MC, eds. Cost-effectiveness in health and medicine. Oxford: Oxford University Press, 1996.
11. O'Brien B, Drummond M, Richardson WS, Levine M, Heyland D, Guyatt G. Economic analysis. In: Guyatt G, Rennie D, eds. Users' guides to the medical literature. Chicago: AMA Press, 2002, 621-44.